BioSpace News Archive

Opthea Limited announced an oral presentation featuring sozinibercept which will be presented at the annual FLORetina Congress being held November 30 to December 3, 2023, in Rome, Italy.

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Officer Christopher Roberts to Chief Financial Officer.

Castle Biosciences, Inc. announced the publication of a study in the Journal of the Advanced Practitioner in Oncology that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.

HanchorBio Inc. today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.

Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease announced the appointment of Andrew Walsh as VP, Finance.

Soligenix, Inc. announced that an article describing the potential use of HyBryte™ in the treatment of cutaneous T-cell lymphoma has been published in Frontiers in Drug Discovery.

Gain Therapeutics, Inc. today announced the publication of preclinical data identifying a novel class of small molecule allosteric regulators that demonstrate therapeutic potential for galactosidase beta 1 (GLB1)-related lysosomal storage disorders (LSDs), including GM1 gangliosidosis.

NeuroPace, Inc. today announced that the Company will have a substantial presence at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orlando, Florida and virtually from December 1-5, 2023.

Kazia Therapeutics Limited today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 4,444,445 of the Company’s American Depositary Shares.

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink.